India's Shilpa Medicare surges to nearly 8-year high on successful drug trial
26/08/2024 05:42
** Shares of Shilpa Medicare SHME.NS rise 9.5% to 764.2
rupees, highest since Dec. 26, 2016
** Set for third-best day so far in 2024
** Co says phase 3 studies of drug for treatment of
nonalcoholic fatty liver disease had successful outcome
** Nifty Pharma index .NIPHARM , which comprises SHME's
peers, up 0.2%; SHME is not part of the index
** SHME up 2.3X YTD vs 34% climb in pharma index
(Reporting by Varun Vyas in Bengaluru)
((varunvyas.hebbalalu@thomsonreuters.com))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026